AbbVie is set to acquire Gilgamesh Pharmaceuticals’ bretisilocin, a next-generation psychedelic compound with promising Phase 2 results for major depressive disorder. The treatment’s short-acting properties and robust clinical data highlight its potential to address critical gaps in current psychiatric therapies.